Physician profile
Paul Stanton
NPI 1669682613
$28,401.76
in general payments reported to CMS, 2019-2025
11 companies · $208 in 2025
The $208 reported for 2025 was less than what a typical Orthopaedic Surgery of The Spine provider received nationally (typical 2025 total: $2,116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,515 · 2020: $12K · 2021: $4,683 · 2022: $1,616 · 2023: $484 · 2024: $98.15 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $395 · Royalty Or License: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $395.23 |
| Royalty Or License | $394.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuvasive, INC. | $27,026.35 | 2019-2023 | Lessray |
| Nevro Corp. | $345.26 | 2019-2024 | Senza |
| Orthofix Medical, INC. | $196.36 | 2021-2025 | Cervical-Stim |
| Providence Medical Technology, INC. | $157.35 | 2019-2021 | |
| Boston Scientific Corporation | $144.41 | 2019-2025 | General - Pain Management |
| Stryker Corporation | $137.40 | 2021 | |
| Spinal Elements, INC. | $130.97 | 2025 | |
| Si-Bone, INC. | $101.86 | 2019-2020 | |
| Centinel Spine, LLC | $73.28 | 2023 | Prodisc L |
| Abbvie INC. | $65.34 | 2024 | |
| Abbott Laboratories | $23.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Stanton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.